SABCS23 Day 4 Highlights by Oncology Brothers

Oncology Brothers have recently shared their highlights from SABCS23. Below we feature the fourth day’s highlights from X/Twitter.

”SABCS23 Day 4 Highlights Community Oncology:

1. NATALEE update
2. INAVO120
3. KN522 update
4. KATHERINE update
5. Summary by Ilana Schlam

1. NATALEE: Adj Ribociclib in HR+ early breast cancer (Stg IIA – III), 400mg daily (3wks on, 1wk off) for 3yrs.

– 3yr iDFS 90.7% vs 87.6, 3.1% absolute iDFS,
– N0 HR: 0.72 & N1-3: 0.76 – OS immature,
– AEs: QTc prolongation, Neutropenia. >50% did not complete 3yrs.

For the more information click here.

2. INAVO120: Ph III, Inavolisib (iPI3Ka) + Fulvestrant + Palbo vs Palbo/Fulvestrant HR+ metastatic breast cancer:

– OS immature (favoring Inavo HR 0.64),
– PFS 15.0 vs 7.3mos (HR 0.43),
– AEs: >50% had hyperglycemia and stomatitis,
– Now, we have Capi, Alpelisib, and Inavo. Capi seems to have the most favorable AEs.

For the more information click here.

3. KN522 current SoC PeriOp IO + neoAdj Chemo and then Adj IO for high risk TNBC. Updates

– Improved pCR in N0 (86.3% vs 77.8%) and N+ (76.8% vs 67%),
– Improved EFS with IO regardless of pCR.

For the more information click here.

4. KATHERINE update at 8.4yrs:

– TDM-1 improves OS w/ residual disease in Her2+ post NACT (absolute OS difference of 4.7% HR: 0.66),
– High CNS recurrence/occurrence in HER2+ remains a big concern,
– KATHERINE reiterates TDM1 as SoC in this setting.

For the more information click here.

5. Beautiful summary algorithms by Ilana Schlam putting SABCS23 and 2023 advancements all together. For the more information click here.”

Source: Oncology Brothers/X